Launching a drug development company with novel technology from academia
Our corporate group has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity
Focused Experience
Launching a drug development company with novel technology from academia
Overview
Do you need legal counsel on the creation of your drug development company?
Our firm has worked with hundreds of entrepreneurs at this stage to help them optimally and efficiently select and form the appropriate legal entity.
Industry Knowledge
A tailored approach
At Faber, all of our work is tailored specifically for each of our clients. This approach allows us to give entrepreneurs personalized, vital advice that they need to launch their companies.
We have the skill, knowledge, and experience to give thoughtful and pragmatic counsel, while our clients are not being burdened by the higher rates of big box firms, which often result in more cookie-cutter approaches.
Based on your unique circumstance, we will counsel you on the optimal source of financing, including:
- Founders’ agreements
- Angel financing
- Venture capital
- Foundation grants
- Government investment programs
- Venture debt
- Equipment financing and capital leasing
- Conventional bank financing
- Royalty financing
- Shareholder agreements
- Equity compensation
We provide every enterprise with a solid foundation to make well considered decisions concerning their early-stage operations, continuation of scientific development, and raising a first full round of equity financing.
There are great efficiencies that can be gained by looking at the big picture and considering with our lawyers the interplay between, and timing of, important early-stage activities such as issuing founders’ equity, securing important in-licenses, and raising seed funding.
In parallel, we can help as you build out your team and other external intellectual resources such as consultants, third-party service providers, scientific advisors and board members.
Key agreement negotiations
Our lawyers have extensive experience structuring and negotiating key in-license agreements with universities and research organizations, which require partnering closely with each clients' scientific and business founders and patent counsel.
These agreements are often critical for securing investment capital and subsequently attracting interest from larger biopharma partners for licensing or acquisition transactions.
We provide value to early stage companies by advising on how these key in-license agreements will be examined and evaluated by larger biopharma partners in the future, and by addressing these future concerns by negotiating key provisions appropriately in the original university in-license.
We are also able to help negotiate and provide practical solutions to later conflicts that may arise between rights desired by a large biopharma sublicensee, and the concerns of the upstream university licensor.
Our team also has broad and deep experience negotiating and advising early stage companies in other agreements they will need put in place to leverage contract research organizations, thought leaders and experts (who may serve on the newco’s scientific advisory board), and sponsored research conducted by universities (including but not limited to the university that owns the core IP technology the company has licensed).
These agreements typically involve services or activities that generate novel intellectual property, whether in the form of patentable inventions, valuable trade secrets or know-how, or key scientific data that may be essential for future clinical trials and product approvals.
We have extensive experience with the key concerns of these contract organizations, experts and universities, and offer timely, pragmatic solutions and language to expedite negotiation and execution so the science team can execute on their objectives.
Recent start-up clients
Vizgen, Inc.
Series B FinancingVizgen raises Series B equity funding from Northpond Ventures LP, ARCH Venture Fund X, L.P., Novalis LifeSciences LLC, Tao Capital Management, Pura Vida Investments and other current investors
Press Release
Artax Biopharma, Inc. + Advent Life Sciences Fund II LP
Series B Financing (Series B4)Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly
Press Release
Summation Bio, Inc.
Series A FinancingSummation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors
Vernal Biosciences, Inc.
Series A FinancingVernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership
Press Release
Viridian Therapeutics, Inc.
Series Seed FinancingSeries Seed Preferred Stock Financing led by Fairmount Funds
Dianthus Therapeutics OpCo, Inc.
Series A FinancingDianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors
Press Release
